vs
Ascendis Pharma A/S（ASND）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
Ascendis Pharma A/S的季度营收约是BRC Group Holdings, Inc.的1.4倍（$267.3M vs $188.3M），Ascendis Pharma A/S同比增速更快（42.3% vs -21.9%），过去两年Ascendis Pharma A/S的营收复合增速更高（60.7% vs -15.4%）
Ascendis Pharma A/S是一家聚焦内分泌疾病治疗领域的生物制药企业，核心业务覆盖生长激素疗法的研发、生产与商业化。其依托重组DNA技术生产的生长激素类处方药物，可用于治疗多种生长激素缺乏相关适应症，临床应用场景广泛。
ASND vs RILY — 直观对比
营收规模更大
ASND
是对方的1.4倍
$188.3M
营收增速更快
ASND
高出64.2%
-21.9%
两年增速更快
ASND
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $267.3M | $188.3M |
| 净利润 | — | $90.3M |
| 毛利率 | 90.5% | 79.5% |
| 营业利润率 | — | 32.3% |
| 净利率 | — | 47.9% |
| 营收同比 | 42.3% | -21.9% |
| 净利润同比 | — | 1710.8% |
| 每股收益（稀释后） | — | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASNDRILY
| Q4 25 | $267.3M | $188.3M | ||
| Q3 25 | $230.7M | $215.3M | ||
| Q2 25 | $170.7M | $188.2M | ||
| Q1 25 | $109.0M | $197.2M | ||
| Q4 24 | $187.8M | $241.0M | ||
| Q3 24 | $62.5M | $225.5M | ||
| Q2 24 | $38.9M | $256.0M | ||
| Q1 24 | $103.6M | $263.4M |
净利润ASNDRILY
| Q4 25 | — | $90.3M | ||
| Q3 25 | $-65.9M | $91.1M | ||
| Q2 25 | $-42.0M | $139.5M | ||
| Q1 25 | $-102.2M | $-10.0M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | $-107.1M | $-284.4M | ||
| Q2 24 | $-118.1M | $-433.6M | ||
| Q1 24 | $-141.5M | $-49.2M |
毛利率ASNDRILY
| Q4 25 | 90.5% | 79.5% | ||
| Q3 25 | 89.5% | 83.7% | ||
| Q2 25 | 80.1% | 81.3% | ||
| Q1 25 | 82.6% | 81.4% | ||
| Q4 24 | 91.9% | 79.8% | ||
| Q3 24 | 80.6% | 82.1% | ||
| Q2 24 | 68.2% | 84.5% | ||
| Q1 24 | 92.1% | 85.3% |
营业利润率ASNDRILY
| Q4 25 | — | 32.3% | ||
| Q3 25 | 5.1% | 30.4% | ||
| Q2 25 | -33.5% | 5.7% | ||
| Q1 25 | -103.2% | -31.2% | ||
| Q4 24 | — | -69.2% | ||
| Q3 24 | -167.3% | -36.4% | ||
| Q2 24 | -370.2% | -90.8% | ||
| Q1 24 | -51.2% | -6.1% |
净利率ASNDRILY
| Q4 25 | — | 47.9% | ||
| Q3 25 | -28.5% | 42.3% | ||
| Q2 25 | -24.6% | 74.1% | ||
| Q1 25 | -93.7% | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -171.5% | -126.1% | ||
| Q2 24 | -303.9% | -169.4% | ||
| Q1 24 | -136.6% | -18.7% |
每股收益（稀释后）ASNDRILY
| Q4 25 | — | $2.78 | ||
| Q3 25 | — | $2.91 | ||
| Q2 25 | — | $4.50 | ||
| Q1 25 | — | $-0.39 | ||
| Q4 24 | — | $-0.01 | ||
| Q3 24 | — | $-9.39 | ||
| Q2 24 | — | $-14.35 | ||
| Q1 24 | — | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $665.3M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $-175.8M | $-171.5M |
| 总资产 | $1.4B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASNDRILY
| Q4 25 | $665.3M | $226.6M | ||
| Q3 25 | $582.2M | $184.2M | ||
| Q2 25 | $533.6M | $267.4M | ||
| Q1 25 | $559.4M | $138.3M | ||
| Q4 24 | $604.3M | $146.9M | ||
| Q3 24 | $675.6M | $159.2M | ||
| Q2 24 | $279.4M | $236.9M | ||
| Q1 24 | $345.9M | $190.7M |
总债务ASNDRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ASNDRILY
| Q4 25 | $-175.8M | $-171.5M | ||
| Q3 25 | $-188.0M | $-260.5M | ||
| Q2 25 | $-202.6M | $-351.7M | ||
| Q1 25 | $-205.0M | $-496.8M | ||
| Q4 24 | $-114.2M | $-488.2M | ||
| Q3 24 | $-105.1M | $-497.6M | ||
| Q2 24 | $-346.8M | $-218.3M | ||
| Q1 24 | $-257.2M | $228.4M |
总资产ASNDRILY
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.2B | $1.7B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $1.2B | $2.2B | ||
| Q2 24 | $819.0M | $3.2B | ||
| Q1 24 | $866.7M | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $58.2M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASNDRILY
| Q4 25 | $58.2M | $26.2M | ||
| Q3 25 | — | $-60.6M | ||
| Q2 25 | — | $-25.6M | ||
| Q1 25 | $-15.5M | $184.0K | ||
| Q4 24 | $-330.7M | $-2.7M | ||
| Q3 24 | — | $19.5M | ||
| Q2 24 | — | $111.5M | ||
| Q1 24 | $-109.7M | $135.4M |
现金转化率ASNDRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASND
暂无分部数据
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
